PROM1 and glioblastoma: Studies have demonstrated that NPs functionalized with anti-CD133 antibodies and loaded with chemotherapeutic agents can effectively target CD133-positive CSCs, leading to tumor outgrowth inhibition in the liver cancer and glioblastoma mouse models28.